Business combinations (Details 2) (Onyx Pharmaceuticals, Inc. [Member], USD $) In Millions, unless otherwise specified	12 Months Ended
Dec. 31, 2013	Dec. 31, 2012
Onyx Pharmaceuticals, Inc. [Member]
Business Acquisition [Line Items]
Pro forma net sales	$ 19,141	$ 17,616
Pro forma net income	$ 4,848	$ 3,700

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(2)-(3)

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Name:	us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration